SCHEMBL7028384

SCHEMBL7028384

Cc1ccc(-n2cc(C)cn2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.47
HPGD P15428 3/20 0.47
ALDH1A1 P00352 3/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
KDM4E B2RXH2 2/20 0.47
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
NOTUM Q6P988 2/20 0.45
TDO2 P48775 1/20 0.44
NPSR1 Q6W5P4 2/20 0.43
MAPK1 P28482 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
KMT2A Q03164 1/20 0.43
CYP1A2 P05177 1/20 0.41
GAA P10253 1/20 0.41
NOS1 P29475 1/20 0.41
FLT3 P36888 2/20 0.41
RXRA P19793 1/20 0.39
GRIN1 Q05586 1/20 0.39
GRIN2B Q13224 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7028379 0.85 TDO2 (0.41) MAPTHPGDALDH1A1SMN1; SMN2KDM4E
SCHEMBL12349894 0.85 GRM4 (0.43) MAPTHPGDALDH1A1SMN1; SMN2KDM4E
SCHEMBL11962623 0.85 TDO2 (0.49) MAPTHPGDALDH1A1SMN1; SMN2KDM4E
SCHEMBL9134518 0.85 ALDH1A1 (0.49) MAPTHPGDALDH1A1KDM4ENPC1
SCHEMBL3095150 0.85 TDO2 (0.41) MAPTHPGDALDH1A1SMN1; SMN2KDM4E
SCHEMBL12988820 0.85 MELK (0.50) MAPTHPGDALDH1A1SMN1; SMN2KDM4E
SCHEMBL255496 0.84 GAA (0.59) MAPTHPGDALDH1A1SMN1; SMN2KDM4E
SCHEMBL9024901 0.83 GRM4 (0.46) MAPTHPGDALDH1A1SMN1; SMN2KDM4E
SCHEMBL10265056 0.82 MAPKAPK2 (0.51) MAPTHPGDALDH1A1SMN1; SMN2KDM4E
SCHEMBL25900771 0.82 ALDH1A1 (0.46) MAPTHPGDALDH1A1SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11771738-B2 Endoparasitic depsipeptides ZOETIS SERVICES LLC (US) 2023-10-03 US disclosed
US-11771738-B2 Endoparasitic depsipeptides ZOETIS SERVICES LLC (US) 2023-10-03 US disclosed
WO-2010115264-A1 INHIBITORS OF HIV REPLICATION BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-10-14 WO disclosed
CN-100497358-C Iridium compound and organic electroluminescent device using the same SAMSUNG SDI CO LTD (KR) 2009-06-10 CN disclosed
US-20030013663-A1 6-O-CARBAMOYL KETOLIDE ANTIBACTERIALS ORTHO-MCNEIL PHARMACEUTICAL, INC. 2003-01-16 US disclosed
US-6472372-B1 6-O-Carbamoyl ketolide antibacterials ORTHO-MCNEIL PHARMACEUTICALS, INC. 2002-10-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030013663-A1 6-O-CARBAMOYL KETOLIDE ANTIBACTERIALS Q6ZSR9, KDM4E, HK1 MAPT 3982/4885HPGD 2320/4885ALDH1A1 3560/4885
US-11771738-B2 Endoparasitic depsipeptides VIP, PREP, VIPR1 MAPT 4773/4885HPGD 1639/4885ALDH1A1 2109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.